Trial document
This study has been imported from ClinicalTrials.gov without additional data checks.
DRKS00005837
Trial Description
Title
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
Trial Acronym
EFACTS
URL of the Trial
[---]*
Brief Summary in Lay Language
This is a multi-centre, multi-national, prospective, observational study of Friedreich's
Ataxia (FRDA) with a control group to:
- obtain natural history data on individuals affected by FRDA
- relate clinical assessments and results from proteomic analyses
- expedite identification and recruitment of participants for clinical trials
- develop and validate sensitive and reliable outcome measures for detecting onset and
change over the natural course of FRDA which may also be potential outcome measures for
use in future clinical trials and clinical care
- plan for future research studies
Brief Summary in Scientific Language
The EFACTS patient registry integrates prospectively and systematically collected clinical
research data (e.g. clinical tests, demographical characteristics) with access to biological
specimens (e.g. blood, urine) obtained from individuals with genetically confirmed FRDA and
unrelated control research participants.
The EFACTS patient registry is a 4-year study and eligible subjects are assessed at annual
study visits on the clinical symptoms and signs of the disease. At each study visit, general
clinical, motor function, cognitive, and Quality of Life assessments are administered. In
addition, participants are providing bio samples for the purposes of genetic testing and for
research to identify valuable biomarkers of FRDA. Biological specimens and clinical data are
made available to qualified scientists within the EFACTS network whose projects are reviewed
and approved by the EFACTS Steering Committee. Research projects should aim to advance
scientific knowledge towards establishing clinically effective treatments that delay onset
and/or slow the progression of the disease.
Organizational Data
- DRKS00005837
- 2015/01/19
- 2014/02/19
- yes
- [---]*
- [---]*
Secondary IDs
- NCT02069509 (ClinicalTrials.gov)
- HEALTH-F2-2010- 242193 (European Friedreich's Ataxia Consortium for Translational Studies)
Health Condition or Problem studied
- Friedreich's Ataxia
- G11.1 - Early-onset cerebellar ataxia
Interventions/Observational Groups
- [---]*
Characteristics
- Non-interventional
- Observational study
- [---]*
- [---]*
- [---]*
- [---]*
- [---]*
- [---]*
- N/A
- [---]*
Primary Outcome
- Disease progression as assessed by clinical examination; time frame: Participants are followed for a max. of 4 years with annual assessments
Secondary Outcome
[---]*
Countries of Recruitment
- Austria
- Belgium
- France
- Germany
- Italy
- Spain
- United Kingdom
Locations of Recruitment
Recruitment
- [---]*
- 2010/05/31
- 650
- Multicenter trial
- International
Inclusion Criteria
- Both, male and female
- no minimum age
- no maximum age
Additional Inclusion Criteria
Inclusion Criteria:
- Genetic diagnosis of FRDA
- For control research participants: genetically confirmed absence of FRDA
Exclusion Criteria
[---]*
Addresses
-
start of 1:1-Block address primary-sponsor
- European Friedreich's Ataxia Consortium for Translational Studies
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address scientific-contact
- University Hospital Aachen, Dept. of Neurology
- Jörg B. Schulz
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Jörg B. Schulz, MD
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- 0049-241-80-89600
- [---]*
- jschulz at ukaachen.de
- [---]*
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact materialSupport
Status
- Recruiting ongoing
- [---]*
Trial Publications, Results and other Documents
- 1
- 2014/02/23